Response to letter entitled Re: Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients.

Persano, Mara; Rimini, Margherita; Casadei Gardini, Andrea

Persano, Mara; Rimini, Margherita; Casadei Gardini, Andrea.

Afiliación

Persano M; Medical Oncology, University and University Hospital of Cagliari, Italy. Electronic address: marapersano@alice.it.
Rimini M; Department of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy.
Casadei Gardini A; Department of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy.

Eur J Cancer ; 192: 113264, 2023 10.

Article en En | MEDLINE | ID: mdl-37620209

Asunto(s)

Carcinoma Hepatocelular; Neoplasias Hepáticas; Humanos; Bevacizumab/efectos adversos; Carcinoma Hepatocelular/tratamiento farmacológico; Neoplasias Hepáticas/tratamiento farmacológico

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Límite: Humans Idioma: En Revista: Eur J Cancer Año: 2023 Tipo del documento: Article

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google